Volume 34 Issue 5
Sep.  2018
Turn off MathJax
Article Contents
Article Navigation >  Journal of Nanjing University of traditional Chinese Medicine  > 2018  >  34(5): 443-447
HUNai-qiang, LINCai-zhi, ZHAOHai-yan, ZHANGLin-ying, XUXue-lei, HANDan, SHAOWen-hui. Effect of Jiubiying Decoction Combined with Chemotherapy on Serum Survinvin， p53 Protein and Immune Function in Elderly Advanced Non-Small Cell Lung Cancer[J]. Journal of Nanjing University of traditional Chinese Medicine, 2018, 34(5): 443-447.
Citation: HUNai-qiang, LINCai-zhi, ZHAOHai-yan, ZHANGLin-ying, XUXue-lei, HANDan, SHAOWen-hui. Effect of Jiubiying Decoction Combined with Chemotherapy on Serum Survinvin， p53 Protein and Immune Function in Elderly Advanced Non-Small Cell Lung Cancer[J]. Journal of Nanjing University of traditional Chinese Medicine, 2018, 34(5): 443-447.
shu

Effect of Jiubiying Decoction Combined with Chemotherapy on Serum Survinvin， p53 Protein and Immune Function in Elderly Advanced Non-Small Cell Lung Cancer

  • 1.

    Department of Preventive Treatment of Disease, Guangxi International Zhuang Medicine Hospital, Nanning, 530221, China

  • 2.

    The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 532022, China

  • 3.

    Yongning District Hospital of Traditional Chinese Medicine, Nanning, 530200, China

  • 4.

    Department of Oncology, Traditional Chinese Medical of Guiping City, Guiping, 537200, China

  • 5.

    Graduate School, Guangxi University of Chinese Medicine, Nanning, 532001, China

  • Received Date: 2018-06-10
  • Publish Date: 2018-09-10
    Abstract
  • OBJECTIVE To observe the clinical efficacy of Jiubiying Decoction combined with DP regimen (docetaxel+cisplatin) in the treatment of elderly patients with advanced non-small cell lung cancer. METHODS 100 elderly patients with advanced non-small cell lung cancer were randomly divided into treatment group and control group， 50 cases in each group. The control group was treated with DP chemotherapy， and the treatment group was given by Jiubiying Decoction on the basis of control group. All of them were treated with 21 days as a cycle and 4 cycles were observed. The changes of tumor size， TCM symptom score， side effects， serum p53， Survivin level and immune status were observed before and after treatment. RESULTS In terms of solid tumor changes， treatment group was superior to control group in total effective and disease control rate (P<0.05). After treatment， the TCM symptom scores， serum p53 and Survivin levels in two groups were lower than those before treatment (P<0.01)， the degree of reduction in treatment group was higher than that in control group (P<0.01). For immune function， the levels of CD3+， CD4+， CD4+/CD8+ in treatment group were significantly higher than those before treatment and control group (P<0.01). For side effects， the cases of myelosuppression and liver damage in treatment group were less than those in control group (P<0.05). CONCLUSION Jiubiying Decoction combined with DP regimen can better control tumor size， improve clinical symptoms， and decrease serum p53 and Survivin levels in elderly patients with advanced non-small cell lung cancer， and have synergistic and attenuating effects.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    程伟雄，吴北林．非小细胞肺癌外周血内皮细胞关系初步探讨[J]．当代医学，2012，16（14）：8-9．
    [2]
    李永颜.91例老年肺癌患者化学治疗后生存期影响因素分析[J].中国药业，2017，26（7）:55-58.
    [3]
    张铭，项怡，徐振晔．益气养精法结合化疗治疗中晚期老年非小细胞肺癌的临床疗效观察及生存期影响因素分析[J]．上海中医药杂志，2013，47(1): 35-38．
    [4]
    王振强，高秀敏，黄如静，等.定痛方联合三阶梯止痛治疗肺癌疼痛临床研究[J].中医学报，2017，32（11）:2044-2048.
    [5]
    林才志，陈文英，胡乃强，等.青年肺癌与老年肺癌临床特点分析[J].广西中医药大学学报，2017，20（1）:16-18.
    [6]
    ETTINGER DS， WOOD DE， AKERLEY W， et al. Non-small cell lung canner (version 6)[J]. JNCCN， 2015，13(5):515-524.
    [7]
    中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002：125-129.
    [8]
    田德禄，蔡淦.中医内科学[M].2版.上海：上海科学技术出版社.2013：412-415.
    [9]
    黎皓思，潘频华，刘湘国，等.2013年湖南省肿瘤登记地区肺癌发病与死亡特征[J].中国肿瘤，2018，27（3）:174-180.
    [10]
    〖JP2〗EISENHAUER EA， THERASSE P， BOQAERTS J， et al. New response evaluation criteria in solid tumours:Revised RECIST guideline(version 1.1)[J]. Eur J Cancer，2009，45(2):228-247.〖JP〗
    [11]
    抗癌药急性及亚急性毒性反应分度标准(WHO标准)[J]．癌症，1992，11(3): 254．
    [12]
    安鸿志，于卫江.顺铂用于非小细胞肺癌化疗的疗效、毒性与时间关联性研究[J].中国药房，2011，22(16):1463-1465.
    [13]
    叶青，王瑞平.中药单体逆转肺癌多药耐药作用的研究进展[J].时珍国医国药，2017，28（1）:193-196.
    [14]
    李积敏.中医妇科疑难病临床经验精华[M].西安：陕西科学技术出版社，1994：163.
    [15]
    许睿.救必应化学成分研究及抗肿瘤活性成分初步筛选[D].广州：广州中医药大学，2009.
    [16]
    丘芬，张兴燊，江海燕，等.救必应水提液对小鼠肝脏病理损害的治疗作用研究[J].亚太传统医药，2015，11（5）:10-12.
    [17]
    赫玉芳.救必应酸的制备及其衍生物的设计、合成和抗肿瘤活性研究[D].长春：吉林大学，2013.
    [18]
    李剑，童希文，韩永香.Survivin mRNA和p53蛋白在肺癌组织中的表达[J].新乡医学院学报，2017，34（2）:147-150.
    [19]
    吴翠翠，修冬莹，张雪琦.肺癌患者血清p53抗体及肺癌组织p53表达对肺癌诊断价值的研究[J].北华大学学报(自然科学版)，2014，15(4):486-489.
    [20]
    LIU JL，WANG Y，JIANG J，et al. Inhibition of survivin expression and mechanisms of reversing drug-resistance of human lung adenocarcinoma cells by siRNA[J]．Chin Med J(Engl)，2010，123(20):2901-2907.
    [21]
    〖JP2〗YIE SM， LOU B， YE SR， et al.Clinical significance of detecting survivin-expressing circulating cancer cells in patients wit non-small cell lung cancer[J]. Lung Cancer， 2009， 63(2):284-290.〖JP〗
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2653) PDF downloads(1876) Cited by()
    Proportional views
    Related

    Copyright © Journal of Nanjing University of traditional Chinese Medicine

    Sponsored by：Nanjing University of traditional Chinese MedicineAddress：No.138 xianlin Avenue, Qixia District, Nanjing cityChina Pos：210023

    Tel：025-85811935Email：xb@njucm.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return